Analytical Data
-
Gene name
CYP2A13
- Application
-
Alternative Names
(CYPIIA13)
-
Species
Human
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q16696
-
Expression Region
1-494aa
-
Molecular Weight
64.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CYP2A13, a member of the cytochrome P450 family, is an important enzyme that primarily catalyzes the metabolism of nicotine and various other xenobiotics. Recent research has shown that CYP2A13 is predominantly expressed in human respiratory tissues and plays a significant role in the activation of procarcinogens present in tobacco smoke, contributing to lung cancer risk associated with smoking. Studies have indicated that genetic polymorphisms in the CYP2A13 gene may influence individual susceptibility to tobacco-related cancers. The full understanding of CYP2A13’s structure, function, and interactions with various substrates can provide insights into its role in drug metabolism, toxicology, and carcinogenesis. The recombinant expression of CYP2A13 in various heterologous systems, such as bacterial or yeast cultures, has facilitated the characterization of this enzyme's kinetic properties and substrate specificity. Through the production of CYP2A13 recombinant protein, researchers aim to elucidate its mechanisms of action, explore potential inhibitors, and investigate its pharmacogenomic implications in personalized medicine. Continued exploration of CYP2A13 is crucial for developing strategies for cancer prevention and for understanding the complexities of drug metabolites within human health and disease contexts.
